Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

ConclusionsMRD combined with CD19 might optimize PRT choices for adult t(8;21) AML patients in CR1.

Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Xi Jia, Naying Liao, Sijian Yu, Huan Li, Hui Liu, Haiyan Zhang, Jun Xu, Yunqian Yao, Han He, Guopan Yu, Qifa Liu, Yu Zhang, Pengcheng Shi Tags: RESEARCH ARTICLE Source Type: research